tiprankstipranks
The Fly

Vir Biotechnology price target lowered to $27 from $41 at Barclays

Vir Biotechnology price target lowered to $27 from $41 at Barclays

Barclays lowered the firm’s price target on Vir Biotechnology to $27 from $41 and keeps an Overweight rating on the shares following quarterly results. Vir highlighted key data update for VIR-2218/VIR-3434 in HBV/HDV at AASLD, the firm pointed out in a research note on Friday. With multiple early stage candidates and strong cash position, Barclays sees long-term upside potential.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on VIR:

Questions or Comments about the article? Write to editor@tipranks.com